Nonhuman primates serve as crucial animal models for exploring the pathogenesis of infectious and noninfectious diseases, and for testing of new therapies and vaccines that cannot be evaluated in small animal models. This grant established the Nonhuman Primate Reagent Resource, a program for developing, manufacturing and distributing antibody-based reagents that deplete specific lymphocyte subpopulations or target specific immune functions in vivo. These novel reagents serve to optimize the use of nonhuman primates across multiple scientific disciplines. We will continue to serve as a resource laboratory, and take advantage of scientific advances and technological improvements by expanding the number and type of reagents we make available to biomedical investigators.

Public Health Relevance

The Nonhuman Primate Reagent Resource develops, manufactures and distributes antibody research reagents for use as tools in nonhuman primate models of disease. These antibody tools help investigators to develop treatments and vaccines for many different infectious diseases. Some antibodies are also being evaluated as therapeutics for autoimmune diseases and in organ transplantation.

National Institute of Health (NIH)
Office of The Director, National Institutes of Health (OD)
Resource-Related Research Projects (R24)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Watson, Harold L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Massachusetts Medical School Worcester
Overall Medical
United States
Zip Code
Srinivasula, Sharat; Gabriel, Erin; Kim, Insook et al. (2017) CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies. PLoS One 12:e0187912
Nishimura, Yoshiaki; Gautam, Rajeev; Chun, Tae-Wook et al. (2017) Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543:559-563
Shin, Jun-Seop; Kim, Jong-Min; Min, Byoung-Hoon et al. (2017) Pre-clinical results in pig-to-non-human primate islet xenotransplantation using anti-CD40 antibody (2C10R4)-based immunosuppression. Xenotransplantation :
Iyer, Smita S; Sabula, Michael J; Mehta, C Christina et al. (2017) Characteristics of HIV target CD4 T cells collected using different sampling methods from the genital tract of HIV seronegative women. PLoS One 12:e0178193
O?Neill, Natalie A; Zhang, Tianshu; Braileanu, Gheorghe et al. (2017) Comparative Evaluation of ?CD40 (2C10R4) and ?CD154 (5C8H1 and IDEC-131) in a Nonhuman Primate Cardiac Allotransplant Model. Transplantation 101:2038-2047
Arnold, Nicole; Meyer, Christine; Engelmann, Flora et al. (2017) Robust gene expression changes in the ganglia following subclinical reactivation in rhesus macaques infected with simian varicella virus. J Neurovirol 23:520-538
Martins, Mauricio A; Tully, Damien C; Shin, Young C et al. (2017) Rare Control of SIVmac239 Infection in a Vaccinated Rhesus Macaque. AIDS Res Hum Retroviruses 33:843-858
Kim, Jaeyoung; Kim, Dong Hyun; Choi, Hyuk Jin et al. (2017) Anti-CD40 antibody-mediated costimulation blockade promotes long-term survival of deep-lamellar porcine corneal grafts in non-human primates. Xenotransplantation 24:
Azimzadeh, Agnes M; Zhang, Tianshu; Wu, Guosheng et al. (2017) Preemptive CD20+ B cell Depletion Attenuates Cardiac Allograft Vasculopathy in CD154-Treated Monkeys. Transplantation 101:63-73
Rife Magalis, Brittany; Nolan, David J; Autissier, Patrick et al. (2017) Insights into the Impact of CD8+ Immune Modulation on Human Immunodeficiency Virus Evolutionary Dynamics in Distinct Anatomical Compartments by Using Simian Immunodeficiency Virus-Infected Macaque Models of AIDS Progression. J Virol 91:

Showing the most recent 10 out of 44 publications